[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"UNC Lineberger Comprehensive Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":797},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,47,80,112,140,166,349,361,390,411,436,456,484,506,528,551,575,605,626,646,668,690,715,739,767],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053502","phase-1-study-of-autologous-car-t-cells-targeting-b7-h3-in-tnbc-ic9-carb7-h3-t-cells-100053502",false,"NCT06347068","Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells","Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer","Inclusion Criteria:\n\nUnless otherwise noted, subjects must meet all of the following criteria to participate in in all phases of the study:\n\n1. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information explained to, understood by and signed by the subject or legally authorized representative.\n2. Age ≥ 18 years at the time of consent.\n3. Karnofsky score of \\> 60% (see APPENDIX VI- Karnofsky Scale))\n4. Histologically confirmed TNBC (ER-, PR-, HER2-negative)\n\n   1. ER- and PR-negative: defined as \\\u003C 1% staining by immunohistochemistry (IHC)\n   2. HER2-negative: defined as IHC 0-1+ or fluorescence in situ hybridization (FISH) ratio \\\u003C 2.0\n\nExclusion Criteria:\n\n1. Patients with a history of symptomatic CNS involvement or multiple metastases requiring whole-brain radiation.\n2. Subjects with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n3. Subject does not have a measurable and or evaluable disease as defined by RECIST 1.1","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed\u002Frefractory triple-negative breast cancer (TNBC).",[27,28,29,30],"Breast Cancer","Relapse","Resistant Cancer","Triple Negative Breast Cancer",[32,33],"cellular therapy","biologic therapy","RECRUITING","2026-07-09",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2024-06-27",{"date":42,"type":21},"2030-05",{"name":44,"class":45},"UNC Lineberger Comprehensive Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100643366","phase-2-olomorasib--pembrolizumab-kras-g12c-mutant-pd-l1-tps-1-49-locally-advanced-or-metastatic-nsclc-100643366","NCT07639242","Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC","Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained up until the point at which the subject receives treatment for the subject to be considered eligible for treatment.\n\nInclusion Criteria:\n\nIn order to participate in this study a subject must meet ALL of the eligibility criteria outlined below.\n\nWritten informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Subject is willing and able to comply with study procedures based on the judgement of the investigator.\n\n* Age ≥ 18 years at the time of consent.\n* Eastern Cooperative Oncology Group performance status (ECOG) of 0-2\n* Subjects must have previously untreated, Stage IIIB-IIIC or Stage IV Non-Small Cell Lung Cancer (NSCLC) not amenable to curative intent treatment.\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1 within 28 days prior to treatment\n* Known KRAS G12C mutation identified on tumor tissue or circulating tumor DNA (ctDNA) as determined by molecular testing performed in a CLIA, CAP or other similarly certified laboratory per local guidelines.\n* Subjects must have a known PD-L1 tumor proportion score (TPS) of 1-49% as determined by an IHC assay in a CLIA, CAP, or other similarly certified laboratory as per local guidelines\n\nExclusion Criteria:\n\n• Subject has a serious pre-existing medical condition(s) that, in the judgment of the Investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest and uncontrolled disease-related pericardial effusion or pleural effusion.",{"count":55,"type":21},60,[57],"PHASE2","This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has a Kirsten Rat Sarcoma Virus (KRAS) G12C mutation and a programmed death-ligand (PD-L1) score between 1% and 49%. The main goal of the study is to determine how long patients live without their cancer worsening after starting treatment, also known as progression-free survival (PFS). Additional goals include evaluating how many patients experience tumor shrinkage or disappearance, how long responses to treatment last, overall survival, and the safety and side effects of the treatment combination. Furthermore, how well the treatment works in patients whose cancer has spread to the brain, outcomes in patients with a lower Eastern Cooperative Oncology Group performance status (ECOG), and whether certain tumor or blood-based biomarkers are associated with treatment response or side effects, if enough patient data is available for analysis.",[60,61,62,63],"Lung Cancer","Lung Cancer (NSCLC)","Locally Advanced NSCLC","Metastatic NSCLC - Non-Small Cell Lung Cancer",[65,66,67,68,69,70],"olomorasib","pembrolizumab","KRAS G12C+mutant","Kirsten Rat Sarcoma Virus G12C+ mutant","programmed death-ligand","PD-L1","NOT_YET_RECRUITING","2026-06-30",{"date":74,"type":38},"2026-07-02",{"date":76,"type":21},"2026-06",{"date":78,"type":21},"2030-06-21",{"name":44,"class":45},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":46},"100582251","combating-cancer-related-fatigue-a-personalized-supportive-care-program-100582251","NCT06860880","Combating Cancer-Related Fatigue: A Personalized Supportive Care Program","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n* Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.\n* Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Confirmed diagnosis of indolent lymphoma, Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma.\n* Significant symptoms of fatigue, as defined by PROMIS Fatigue score \\>50.\n\nExclusion Criteria:\n\n* Other co-existing malignancies.\n* Significant cognitive impairment as defined by Mini-Cog score 0-2 (out of 5) that would prevent understanding of assessments or interventions.\n* Unstable or serious illness (e.g., unstable cardiac arrhythmia, severe anemia\u002Fthrombocytopenia) that would prevent safe participation in an exercise regimen, per the discretion of the treating physician.\n* Individuals who are not able to consume an oral diet, due to swallowing difficulties or other reasons, as this might interfere with the nutritional intervention",{"count":87,"type":21},40,[89],"NA","This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30 subjects with chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL) and 10 subjects with Follicular Lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma (CTCL) will be included.",[92,93,94,95,96,97,98,99,100],"Indolent Lymphomas","Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Lymphoplasmacytic Lymphoma","Waldenstrom Macroglobulinemia","Cutaneous T Cell Lymphoma",[102,103],"exercise","dietary intervention","2026-06-29",{"date":106,"type":38},"2026-07-01",{"date":108,"type":38},"2025-06-03",{"date":110,"type":21},"2026-12-31",{"name":44,"class":45},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":119,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100471048","urine-hpv-testing-for-cervical-cancer-screening-among-women-living-with-hiv-in-south-africa-100471048","NCT05413798","Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa","Clinical Performance Validation of Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa","Inclusion Criteria:\n\nIn order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n1. Confirmed HIV-1 infection\n2. Age 25 years and older.\n3. Be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or intend to become pregnant within 90 days of enrollment\n2. Have been screened for cervical cancer within the preceding year (365 days)\n3. Have an active sexually transmitted infection (STI; women may participate once treated)\n4. Have a surgically absent cervix\n5. Have a history of cervical cancer\n6. have been vaccinated against HPV.","FEMALE","25 Years",{"count":122,"type":21},300,[89],"The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women.\n\nCervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.",[126,127,128],"Cervical Cancer","CIN2","CIN3",[130,131,132,133],"cervical cancer","HPV","urine test","HIV",{"date":106,"type":38},{"date":136,"type":38},"2023-05-11",{"date":138,"type":21},"2026-08",{"name":44,"class":45},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100643635","phase-2-revumenib-azacitidine-and-venetoclax-in-newly-diagnosed-kmt2a-rearranged-aml-100643635","NCT07605949","Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML","RAVEN","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age 18-65 years at the time of consent.\n* Untreated AML based on 2022 WHO or ICC criteria with KMT2A translocation by local standard diagnostic testing by cytogenetics\u002Fkaryotype or FISH\n\nExclusion Criteria:\n\n* Isolated myeloid sarcoma (patients must have blood or marrow involvement with AML to enter study)\n* Active central nervous system (CNS) involvement by AML. Of note, patients are eligible if CNS leukemia is in remission at the time of study entry.\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).","65 Years",{"count":149,"type":21},88,[57],"This study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with a specific type of acute myeloid leukemia (AML) called KMT2A- translocated AML.\n\nPeople with this type of AML often have poor outcomes, so new treatments are needed that may work better and cause fewer side effects.\n\nThe study has two parts:\n\n1. Induction Phase: Patients will receive treatment for up to 3 cycles. Each cycle lasts 28 days. The goal is to help the leukemia go into remission.\n2. Continuation Phase: After remission and blood count recovery, patients will continue treatment until the leukemia returns, side effects become too severe, the patient receives a stem cell transplant, or another reason to stop treatment occurs.\n\nPatients who receive an allogeneic stem cell transplant (stem cells from a donor) may also join a separate part of the study to test revumenib as maintenance treatment after transplant.",[153],"Leukemia Acute Myeloid",[155,156,157,158],"revumenib","azacitidine","venetoclax","allogeneic stem cell transplant","2026-06-26",{"date":72,"type":38},{"date":162,"type":21},"2026-07",{"date":164,"type":21},"2028-07",{"name":44,"class":45},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":186,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":348},"100143410","registry-of-older-patients-with-cancer-100143410","NCT01137825","Registry of Older Patients With Cancer","Carolina Senior: UNC Registry for Older Cancer Patients","DISEASE CHARACTERISTICS:\n\n* Patients must have an appointment at the North Carolina Cancer Hospital and agree to complete the Geriatric Assessment NOTE: Not all patients included in the registry will ultimately be diagnosed with cancer. Patients who complete a GA and are not diagnosed with cancer will remain in the database, but will be categorized into a separate group and will not have their medical records accessed.\n\nPATIENT CHARACTERISTICS:\n\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified",{"count":174,"type":21},3000,"OBSERVATIONAL","RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.\n\nPURPOSE: This research study is gathering information from older patients with cancer into a registry.",[178,179,180,93,181,182,183,184,185],"Chronic Myeloproliferative Disorders","Cognitive\u002FFunctional Effects","Leukemia","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340],"cognitive\u002Ffunctional effects","unspecified adult solid tumor, protocol specific","accelerated phase chronic myelogenous leukemia","acute undifferentiated leukemia","adult acute lymphoblastic leukemia in remission","adult acute myeloid leukemia in remission","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","adult acute myeloid leukemia with inv(16)(p13;q22)","adult acute myeloid leukemia with t(15;17)(q22;q12)","adult acute myeloid leukemia with t(16;16)(p13;q22)","adult acute myeloid leukemia with t(8;21)(q22;q22)","atypical chronic myeloid leukemia, BCR-ABL negative","blastic phase chronic myelogenous leukemia","chronic myelomonocytic leukemia","chronic phase chronic myelogenous leukemia","mast cell leukemia","meningeal chronic myelogenous leukemia","progressive hairy cell leukemia, initial treatment","prolymphocytic leukemia","recurrent adult acute lymphoblastic leukemia","recurrent adult acute myeloid leukemia","recurrent adult T-cell leukemia\u002Flymphoma","refractory chronic lymphocytic leukemia","refractory hairy cell leukemia","relapsing chronic myelogenous leukemia","secondary acute myeloid leukemia","stage 0 chronic lymphocytic leukemia","stage I adult T-cell leukemia\u002Flymphoma","stage I chronic lymphocytic leukemia","stage II adult T-cell leukemia\u002Flymphoma","stage II chronic lymphocytic leukemia","stage III adult T-cell leukemia\u002Flymphoma","stage III chronic lymphocytic leukemia","stage IV adult T-cell leukemia\u002Flymphoma","stage IV chronic lymphocytic leukemia","T-cell large granular lymphocyte leukemia","untreated adult acute lymphoblastic leukemia","untreated adult acute myeloid leukemia","untreated hairy cell leukemia","recurrent adult Hodgkin lymphoma","stage I adult Hodgkin lymphoma","stage II adult Hodgkin lymphoma","stage III adult Hodgkin lymphoma","stage IV adult Hodgkin lymphoma","anaplastic large cell lymphoma","angioimmunoblastic T-cell lymphoma","cutaneous B-cell non-Hodgkin lymphoma","recurrent cutaneous T-cell non-Hodgkin lymphoma","stage I cutaneous T-cell non-Hodgkin lymphoma","stage II cutaneous T-cell non-Hodgkin lymphoma","stage III cutaneous T-cell non-Hodgkin lymphoma","stage IV cutaneous T-cell non-Hodgkin lymphoma","recurrent mycosis fungoides\u002FSezary syndrome","stage I mycosis fungoides\u002FSezary syndrome","stage II mycosis fungoides\u002FSezary syndrome","stage III mycosis fungoides\u002FSezary syndrome","stage IV mycosis fungoides\u002FSezary syndrome","adult grade III lymphomatoid granulomatosis","adult nasal type extranodal NK\u002FT-cell lymphoma","Waldenstrom macroglobulinemia","extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","nodal marginal zone B-cell lymphoma","splenic marginal zone lymphoma","contiguous stage II adult Burkitt lymphoma","contiguous stage II adult diffuse large cell lymphoma","contiguous stage II adult diffuse mixed cell lymphoma","contiguous stage II adult diffuse small cleaved cell lymphoma","contiguous stage II adult immunoblastic large cell lymphoma","contiguous stage II adult lymphoblastic lymphoma","contiguous stage II grade 1 follicular lymphoma","contiguous stage II grade 2 follicular lymphoma","contiguous stage II grade 3 follicular lymphoma","contiguous stage II mantle cell lymphoma","contiguous stage II marginal zone lymphoma","contiguous stage II small lymphocytic lymphoma","stage I adult Burkitt lymphoma","stage I adult diffuse large cell lymphoma","stage I adult diffuse mixed cell lymphoma","stage I adult diffuse small cleaved cell lymphoma","stage I adult immunoblastic large cell lymphoma","stage I adult lymphoblastic lymphoma","stage I grade 1 follicular lymphoma","stage I grade 2 follicular lymphoma","stage I grade 3 follicular lymphoma","stage I mantle cell lymphoma","stage I marginal zone lymphoma","stage I small lymphocytic lymphoma","noncontiguous stage II adult Burkitt lymphoma","noncontiguous stage II adult diffuse large cell lymphoma","noncontiguous stage II adult diffuse mixed cell lymphoma","noncontiguous stage II adult diffuse small cleaved cell lymphoma","noncontiguous stage II adult immunoblastic large cell lymphoma","noncontiguous stage II adult lymphoblastic lymphoma","noncontiguous stage II grade 1 follicular lymphoma","noncontiguous stage II grade 2 follicular lymphoma","noncontiguous stage II grade 3 follicular lymphoma","noncontiguous stage II mantle cell lymphoma","noncontiguous stage II marginal zone lymphoma","noncontiguous stage II small lymphocytic lymphoma","stage III adult Burkitt lymphoma","stage III adult diffuse large cell lymphoma","stage III adult diffuse mixed cell lymphoma","stage III adult diffuse small cleaved cell lymphoma","stage III adult immunoblastic large cell lymphoma","stage III adult lymphoblastic lymphoma","stage III grade 1 follicular lymphoma","stage III grade 2 follicular lymphoma","stage III grade 3 follicular lymphoma","stage III mantle cell lymphoma","stage III marginal zone lymphoma","stage III small lymphocytic lymphoma","stage IV adult Burkitt lymphoma","stage IV adult diffuse large cell lymphoma","stage IV adult diffuse mixed cell lymphoma","stage IV adult diffuse small cleaved cell lymphoma","stage IV adult immunoblastic large cell lymphoma","stage IV adult lymphoblastic lymphoma","stage IV grade 1 follicular lymphoma","stage IV grade 2 follicular lymphoma","stage IV grade 3 follicular lymphoma","stage IV mantle cell lymphoma","stage IV marginal zone lymphoma","stage IV small lymphocytic lymphoma","recurrent adult Burkitt lymphoma","recurrent adult diffuse large cell lymphoma","recurrent adult diffuse mixed cell lymphoma","recurrent adult diffuse small cleaved cell lymphoma","recurrent adult grade III lymphomatoid granulomatosis","recurrent adult immunoblastic large cell lymphoma","recurrent adult lymphoblastic lymphoma","recurrent grade 1 follicular lymphoma","recurrent grade 2 follicular lymphoma","recurrent grade 3 follicular lymphoma","recurrent mantle cell lymphoma","recurrent marginal zone lymphoma","recurrent small lymphocytic lymphoma","intraocular lymphoma","post-transplant lymphoproliferative disorder","chronic eosinophilic leukemia","chronic neutrophilic leukemia","primary myelofibrosis","essential thrombocythemia","polycythemia vera","extramedullary plasmacytoma","isolated plasmacytoma of bone","stage I multiple myeloma","stage II multiple myeloma","stage III multiple myeloma","primary systemic amyloidosis","refractory multiple myeloma","de novo myelodysplastic syndromes","previously treated myelodysplastic syndromes","secondary myelodysplastic syndromes","myelodysplastic\u002Fmyeloproliferative neoplasm, unclassifiable","2026-06-24",{"date":104,"type":38},{"date":344,"type":4},"2009-09",{"date":346,"type":21},"2030-12",{"name":44,"class":45},7,{"id":350,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":25,"conditions":353,"keywords":354,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":359,"leadSponsor":360,"locationsCount":46},"100542761",{"count":20,"type":21},[24],[27,28,29,30],[32,33],"2026-06-23",{"date":357,"type":38},"2026-06-25",{"date":40,"type":38},{"date":42,"type":21},{"name":44,"class":45},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":368,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":46},"100628607","artificial-intelligence-ai-enhanced-pretreatment-peer-review-process-to-improve-patient-safety-in-radiation-oncology-100628607","NCT07463833","Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology","Development and Assessment of Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\nProviders only\n\n* ≥18 years\n* Peer-review attendees at participating clinics\n\nPatients only\n\n* ≥18 years\n* All patients with prostate cancer radiation therapy cases treated at participating sites (no intervention delivered to patients)\n\nExclusion Criteria:\n\nProviders only\n\n• Providers unwilling\u002Funable to comply with study procedures; sites unable to implement the workflow or provide required outcomes.\n\nPatients and Providers\n\n• Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rendering of informed consent",true,{"count":370,"type":21},207,[89],"This prospective study will test artificial intelligence (AI) and machine learning (ML) decision support tools. This tool is designed to help doctors, physicists and other staff during pre-treatment peer review, a step where treatment plans are checked before a patient begins care.\n\nThe system highlights summaries showing how different providers may vary in their treatment planning (provider-variability summaries) and points out the best signals or warning signs to look for (optimal cues). By drawing attention to these patterns and cues, the tool aims to help reviewers spot possible treatment-planning mistakes earlier, reduce the chance of errors, and improve overall patient safety.",[374,375],"Cancer","Prostate Cancer",[377,378,379,380,381,382,383],"radiation therapy","artificial intelligence (AI)","machine learning (ML)","radiation therapy (RT)","intensity-modulated radiation therapy (IMRT)","Volumetric Modulated Arc Therapy (VMAT)","Image-guided radiation therapy (IGRT)","2026-06-22",{"date":355,"type":38},{"date":384,"type":38},{"date":388,"type":21},"2027-07",{"name":44,"class":45},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100616319","overcoming-barriers-to-uptake-of-cascade-screening-100616319","NCT07304063","Overcoming Barriers to Uptake of Cascade Screening","Let's Talk: Overcoming Barriers to Uptake of Cascade Screening Through a Stakeholder-informed Online Intervention","Inclusion Criteria for Patients\n\n* Written informed consent obtained to participate in the study.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Written informed consent obtained to participate in the study.\n* Self-reported Lynch syndrome diagnosis.\n\nInclusion Criteria for Genetic Counselor\n\n* Written informed consent obtained to participate in the study.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Written informed consent obtained to participate in the study.\n* Self-reported employment as a practicing genetic counselor at a medical institution.\n\nExclusion Criteria for Patients\n\n* The patient has already notified all relatives about their diagnosis with Lynch syndrome.\n\nExclusion Criteria for Genetic Counselor\n\n* Genetic Counselor is not employed.",{"count":398,"type":21},20,[89],"Lynch syndrome is a genetic condition that increases cancer risk. The public health impact of genetic testing for disease prevention hinges on cascade screening, which is the systematic identification and testing of blood relatives after a family member has been diagnosed with a genetic condition. Despite its importance in disease prevention, only half of first-degree relatives of individuals with Lynch syndrome undergo cascade screening. To address this gap, the study will pilot test an online version of Let's Talk, a novel intervention designed to support and promote cascade screening. This intervention tool is designed to support and encourage more family members to get screened. The purpose of this study aim is to assess the feasibility of the online Let's Talk tool in clinical use by examining implementation and effectiveness outcomes related to the use of the planning tool across three clinics at a large academic-affiliated medical center with patients (n=15) seen by one of five genetic counselors (n=5).",[402],"Lynch Syndrome",[404,405],"Screening","cascade screening",{"date":355,"type":38},{"date":162,"type":21},{"date":409,"type":21},"2026-10",{"name":44,"class":45},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":368,"sex":119,"minAge":418,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100615550","uniting-trusted-community-messengers-to-improve-access-to-cervical-cancer-screening-in-rural-north-carolina-100615550","NCT07294066","Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina","Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina Aim 3","Woman participants\n\nInclusion Criteria:\n\n* Resident of Lenoir County and 12 community.\n* have not received a Pap test within the last 3.5 years, or an HPV test in the last 5.5 years\n* female ≥ 30 to 64 years of age at time of recruitment\n\nExclusion Criteria:\n\n* 65 years of age or older had a hysterectomy,\n* history of cervical cancer,\n* plan to move from Lenoir County during the study period.\n\nCommunity partners participants\n\nInclusion Criteria:\n\n* community health workers\n* clinic staff\n* community-based organization staff.\n\nExclusion Criteria:\n\n• None","30 Years","64 Years",{"count":421,"type":21},112,[89],"The purpose of this study is to test the feasibility and acceptability of a multi-level, community-engaged intervention to increase access to cervical cancer screening using human papillomavirus (HPV) self-collection (HPVSC) outreach among women living in a high-risk rural county and to improve navigation for follow-up screening.\n\nA one-group intervention evaluation design will be used to pilot test feasibility and acceptability and to assess the proportion of women who return HPVSC kits and test HPV-positive. At the community level, local community-based organizations (CBOs) will serve as HPVSC kit distribution sites. At the individual level, trained community health workers will work with CBOs to support women throughout the HPVSC process, including specimen collection, kit return, result notification, and follow-up clinic-based screening for women who test HPV-positive.",[425,426],"Cervix Cancer","Screen HPV-positive",[404,428,429,430],"rural","outreach","high risk",{"date":355,"type":38},{"date":162,"type":21},{"date":434,"type":21},"2029-03",{"name":44,"class":45},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":368,"sex":17,"minAge":442,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":46},"100610337","consumer-perceptions-of-alcoholic-beverages-100610337","NCT07226271","Consumer Perceptions of Alcoholic Beverages","Inclusion Criteria:\n\n* Adults ages 21 years and older\n* Consumed alcohol at least once in the last year\n* Able to complete a survey in English\n\nExclusion Criteria:\n\n\\- Not living in the US","21 Years","99 Years",{"count":445,"type":21},1500,[89],"This study aims to examine the effects of marketing claims on alcoholic beverage packaging on alcohol consumers' perceptions and intentions. Participants will be randomized to view three images of alcoholic beverages (beer, hard seltzer, flavored malt beverage) with one of three marketing claims (or a no claim control), and then queried about their perceptions of the product and intentions to consume the product.",[449],"Health Behavior",{"date":357,"type":38},{"date":452,"type":38},"2025-10-10",{"date":454,"type":21},"2026-09-17",{"name":44,"class":45},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":464,"minAge":18,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":46},"100570080","virtual-testis-cancer-lay-support-and-survivorship-aim-2-100570080","NCT06702592","Virtual Testis Cancer Lay Support and Survivorship Aim 2","Virtual Testicular Cancer Lay Support and Survivorship (VITALSS Study) Aim 2","VITALSS","Inclusion Criteria:\n\n* Men within 5 years of their initial diagnosis of germ cell testicular cancer.\n* The subject is willing and able to comply with study procedures based on the judgment of the investigator.\n* Adults aged 18-95 years old.\n* Electronic informed consent was obtained to participate in the study.\n\nExclusion Criteria:\n\n* Woman gender\n* Non-English speaking\n* Unwilling or unable to complete informed consent.\n* On active treatment for another cancer.\n* Actively receiving chemotherapy, radiation, or surgery for testicular cancer.","MALE","95 Years",{"count":467,"type":21},360,[89],"This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.",[471,472],"Testicular Cancer","Testis Cancer",[474,475,476,477,478],"virtual support","emotional well-being","self-efficacy","financial toxicity","quality of life",{"date":355,"type":38},{"date":162,"type":21},{"date":482,"type":21},"2028-06",{"name":44,"class":45},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":368,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":498,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":46},"100518096","evaluation-of-impact-of-ai-assistance-on-workload-associated-w-preparation-of-rare-tumor-case-repts-100518096","NCT06026098","Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts","A Prospective Evaluation of Impact of AI Assistance on Workload Associated With Preparation of Rare Tumor Case Reports","Inclusion Criteria:\n\n1\\. The subject is a physician, medical student, or postdoctoral student.\n\nExclusion Criteria:",{"count":492,"type":21},10,[89],"The goal of this study is to explore cognitive burden perceptions among physicians in relation to case report writing. Furthermore, this study evaluates the use of artificial intelligence (AI) assistance as a tool to reduce cognitive burden among providers preparing and submitting case reports. If an AI-tool is helpful in this setting, it may potentially help increase reporting of rare medical events and thereby improve the evidence base for care of these patient populations. This study will occur at a single time point which is expected to last approximately 2 hours. This session will include reviewing two rare tumor cases and then writing a clinical vignette with and without AI assistance.",[496,497],"Cognitive Burden","Cognitive Symptom",[499,500],"artificial intelligence","case report",{"date":355,"type":38},{"date":409,"type":21},{"date":504,"type":21},"2026-12",{"name":44,"class":45},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":46},"100133027","correlation-of-molecular-markers-with-response-to-therapy-and-breast-cancer-behavior-100133027","NCT01000883","Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior","Inclusion Criteria:\n\nHigh suspicion of or known breast cancer (early or metastatic)\n\nLesion accessible for safe biopsy (as deemed by the treating physician).\n\nAge ≥ 18 years.\n\nECOG performance status 0 - 2.\n\nAbility to understand and willingness to sign an informed consent document.\n\nIf receiving therapeutic anticoagulation; it should be discontinued temporarily prior to biopsy for a length of time to be determined by the study doctor.\n\nAdequate marrow function, defined as absolute neutrophil count ≥ 1.5 x 109\u002FL and platelets ≥ 100 x 109\u002FL required only for biopsies of vital organs (lung, liver, etc.)\n\nExclusion Criteria:\n\nConcurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety.\n\nDementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n\nHistory of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine)\n\nPregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of conscious sedation, which is required for biopsies of certain anatomic sites (e.g. liver, lung). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.\n\nCardiac disease making it unsafe to biopsy in the opinion of the treating physician.\n\nIf patients receiving bevacizumab or other angiogenesis inhibitors are less than 6 weeks from last dose of the angiogenesis inhibitor, they should not undergo research core biopsies of vital organs (lung, liver, etc.) on this protocol because of the concern for the possibility of increased bleeding risk and delayed healing. Patients receiving bevacizumab or other angiogenesis inhibitors who are undergoing a research biopsy of the breast, peripheral lymph node or a skin punch biopsy must be two weeks from the last dose of the angiogenesis inhibitor.",{"count":513,"type":21},10000,"RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.\n\nPURPOSE: This research study is looking at tissue and blood samples from women with locally advanced or metastatic breast cancer",[27],[517,518,519,520,521],"stage IIIA breast cancer","stage IIIB breast cancer","stage IIIC breast cancer","stage IV breast cancer","recurrent breast cancer",{"date":357,"type":38},{"date":524,"type":38},"1998-12-01",{"date":526,"type":21},"2032-11",{"name":44,"class":45},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":550},"100644187","improving-affordability-in-cancer-care-through-economic-screening-and-support-i-access-100644187","NCT07664436","Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS)","I-ACCESS","Inclusion Criteria:\n\n* Patients: Treatment for cancer at study site, over age 18 years, speak\u002Fread English or Spanish; Caregivers: Identified caregiver of a patient with cancer offered financial hardship screening, over age 18 years, speak\u002Fread English or Spanish; Staff\u002FClinicians: Involvement with I-ACCESS pilot implementation; over age 18 years, speak\u002Fread English or Spanish\n\nExclusion Criteria:\n\n* Unable to read of speak English or Spanish\n* Under the age of 18 years old",{"count":536,"type":21},220,[89],"Screening and referral program to proactively identify financial hardship in adult patients with cancer and connect those at-risk with education, counseling, and resources. Patients with cancer will be screened as part of routine care and referred to available resources at their institution, following the referral processes developed and mapped in Aim 1.",[374,540,541,542],"Financial Burden","Financial Toxicity","Screening Tool","2026-06-17",{"date":341,"type":38},{"date":546,"type":21},"2027-09-01",{"date":548,"type":21},"2029-09-01",{"name":44,"class":45},4,{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":368,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":22,"phases":560,"briefSummary":561,"conditions":562,"keywords":565,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":46},"100615765","homegrown-a-family-based-lifestyle-intervention-to-support-healthy-development-of-young-children-with-down-syndrome-100615765","NCT07296861","HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down Syndrome","HomeGrown","Inclusion Criteria:\n\nAdult:\n\n* Ability to provide informed consent\n* 18 years or older\n* Primary caregiver of a child with Down syndrome aged 2 to 6 years old\n* Have access to WI-FI or smartphone\n* Be able to read and speak English\n\nChildren:\n\n* Be 2-6 years old.\n* Are diagnosed with Down syndrome\n* Are not reliant on tube feeding\n\nExclusion Criteria:\n\n\\-",{"count":559,"type":21},38,[89],"The goal of this project is to evaluate an adapted health promotion program, HomeGrown, designed to improve the health of young children with Down syndrome by supporting families in making healthy home environmental changes. There is a significant need for evidence-based programs that address healthy eating and physical activity within this population, as most existing interventions have been developed for typically developing children. By tailoring the program to the unique needs of families of young children with Down syndrome, this project aims to advance inclusion and equity in health behavior promotion.\n\nThis R61\u002FR33 study will assess the feasibility (R61 Phase) and subsequent efficacy (R33 Phase) of the HomeGrown program in improving family practices related to nutrition and physical activity. During the R61 feasibility phase, 38 primary caregivers of children aged 2-6 years with Down syndrome will be enrolled in a 6-month randomized controlled trial. Families will be randomized 1:1 to either the HomeGrown intervention or a waitlist control group (6-month delayed start), stratified by the child's biological sex (male\u002Ffemale) and age (2-3 vs. 4-6 years). All measures will be collected at baseline and at 6-month follow-up.\n\nThe R61 feasibility phase will address three specific aims:\n\nAccrual: Achieve an enrollment rate of 10 families per month, supporting feasibility for the R33 efficacy phase.\n\nEngagement: Demonstrate that families use at least 70% of available HomeGrown intervention components, measured using the digital behavior change interventions engagement scale.\n\nData Collection \\& Retention: Achieve at least 80% retention with completion of all outcome assessments.\n\nBy addressing key gaps in nutrition and physical activity research for young children with Down syndrome, this study has the potential to improve health outcomes for an underserved population and inform future clinical and community health promotion efforts.",[563,564],"Down Syndrome","Child Obesity",[566],"home environmental","2026-06-09",{"date":569,"type":38},"2026-06-10",{"date":571,"type":38},"2026-04-16",{"date":573,"type":21},"2027-05",{"name":44,"class":45},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":368,"sex":17,"minAge":582,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":591,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":46},"100643735","strength-training-exercise-in-pediatric-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-step-all-100643735","NCT07634653","Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)","STEP-ALL","Inclusion Criteria for children:\n\nAll subjects must meet the following criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. OR Written assent and parental\u002Flegal guardian consent.\n* Age \\>= 6 and \\\u003C =21 years at the time of diagnosis.\n* Newly- diagnosed with one of the following diseases: B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\n\nExclusion Criteria for children:\n\n* Subjects must not be receiving any investigational or additional anti-cancer medicines during induction.\n* Significant concurrent disease, illness, or psychiatric disorder or social issue that would compromise subject safety or adherence to the protocol treatment or procedures, interfere with consent, study participation, follow-up, or interpretation of the study results.\n\nOptional caregiver participation:\n\nInclusion Criteria :All caregivers must meet the following criteria\n\n* Written informed consent to participate in the caregiver interviews.\n* The caregiver must be a parent or legal guardian ≥ 18 years old, and their child must be \\\u003C18 years","6 Years",{"count":87,"type":21},[89],"Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment. These can include tiredness, weak muscles, pain, nerve problems, difficulty moving, and other physical challenges. Many children with ALL are also overweight at diagnosis, and weight gain often continues during treatment. As a result, about half of childhood leukemia survivors have a BMI at or above the 85th percentile.\n\nTreatment decisions are usually based on a child's symptoms and genetic risk factors. However, some risk factors such as physical activity can be modified. Exercise during treatment may help children feel better and may even improve survival. However, research on early symptom tracking and structured exercise during the first phase of chemotherapy is limited, uses different methods, and often does not include reliable patient-reported symptoms.\n\nEffective exercise programs for children with ALL and lymphoblastic lymphoma need to consider the child's age, treatment side effects, motivation, family support, and ways to encourage long-term behavior change. Because children spend little time in the hospital during the induction phase, a mix of in-person and virtual sessions supported by real-time Zoom instruction can make it possible to offer safe and supervised exercise at home.\n\nThis study will use a guided exercise plan that includes tools to track sets, repetitions, intensity, warm-up time, and perceived exertion. These tools help with consistent monitoring and support both patients and caregivers throughout the program. Twenty children newly diagnosed with ALL or lymphoblastic lymphoma who receive standard 3-4 drug induction chemotherapy will be invited to participate. Our goal is to determine whether a 9-week hybrid exercise program, combined with weekly symptom check-ins, is practical and achievable in both hospital and home settings.",[180,587,588,589,590],"Acute Leukemia","Acute Lymphoid Leukemia","Lymphoblastic Lymphoma","Acute Lymphoblastic Leukemia",[592,593,594,595,596,597,598],"children","pediatric","weight gain","body mass index (BMI)","physical activity","Exercise","hybrid exercise program","2026-06-08",{"date":569,"type":38},{"date":599,"type":21},{"date":603,"type":21},"2028-06-01",{"name":44,"class":45},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":46},"100528236","phase-1-autologous-car-t-cells-targeting-b7-h3-in-pdac-100528236","NCT06158139","Autologous CAR-T Cells Targeting B7-H3 in PDAC","A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)","Inclusion Criteria:\n\n1. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for releasing personal health information explained to, understood by, and signed by the subject or legally authorized representative.\n2. Age ≥ 18 years at the time of consent.\n3. Eastern Cooperative Oncology Group of 0-1 Performance Status)\n4. Histological or cytological evidence\u002Fconfirmation of pancreatic ductal adenocarcinoma.\n5. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n6. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.\n\nExclusion Criteria:\n\n1. Subjects with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n2. Subject is not willing and able to comply with study procedures based on the judgment of the investigator.",{"count":613,"type":21},27,[24],"The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.",[617,28,29],"Pancreas Cancer",[32],"2026-06-05",{"date":599,"type":38},{"date":622,"type":38},"2024-07-18",{"date":624,"type":21},"2030-04",{"name":44,"class":45},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":22,"phases":635,"briefSummary":636,"conditions":637,"keywords":638,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":642,"completionDateStruct":643,"leadSponsor":645,"locationsCount":46},"100633431","phase-2-study-on-treatment-outcome-patterns-for-patients-with-cll-after-discontinuation-of-btk-inhibitors-100633431","NCT07526597","Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors","STOP-CLL-DCT","Inclusion Criteria:\n\nIn order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Eastern Cooperative Oncology Group Performance Status of 0-3 or Karnofsky Performance Status of ≥40\n* Confirmed of a diagnosis of CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma) according to International Workshop on Chronic Lymphocytic Leukemia 2018 Guidelines at any point prior to study enrollment.\n* At the time of enrollment, patients must be receiving treatment with a covalent Bruton tyrosine kinase inhibitor in the first or second line setting and have been receiving this treatment for at a minimum 2 years. Patients may have previously received anti-CD20 monoclonal antibodies (such as rituximab or obinutuzumab) in combination with the cBTKi.\n\nExclusion Criteria:\n\n* Patients must not have evidence of progressive CLL as defined by IWCLL 2018 criteria.\n* Participants with history of malignancy other than CLL\u002FSLL are allowed",{"count":634,"type":21},45,[57],"This Phase II hybrid decentralized multicenter study examines the outcomes of stopping Bruton tyrosine kinase inhibitor (BTKi) therapy in patients with chronic lymphocytic leukemia (CLL) who have remained in remission for at least two years. The primary objective is to determine how long patients remain free from disease progression or death after discontinuing treatment, measured as event free survival.\n\nThe study also evaluates whether stopping BTKi therapy leads to improvements in quality of life and reductions in treatment related side effects. Researchers will follow patients over time to assess if the cancer returns, whether resistance to therapy develops, and how patients feel during the treatment free period.\n\nIn addition, the trial will investigate how discontinuing BTKi therapy affects immune function, including whether immune recovery occurs and infection risk decreases.\n\nPreliminary data indicate that patients may experience a treatment free interval exceeding two years after stopping therapy, with associated improvements in quality of life. By prospectively evaluating a time limited treatment strategy, this trial aims to determine whether durable disease control can be maintained off therapy while also assessing the resolution of BTKi related adverse events and changes in patient reported outcomes.\n\nOverall, the study seeks to determine whether patients can safely discontinue BTKi therapy and potentially restart treatment later if needed, thereby maintaining disease control while reducing the burden of continuous therapy.",[94,95],[639],"Bruton's tyrosine kinase inhibitors (BTKi)","2026-06-04",{"date":599,"type":38},{"date":162,"type":21},{"date":644,"type":21},"2032-06",{"name":44,"class":45},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":22,"phases":654,"briefSummary":655,"conditions":656,"keywords":657,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":665,"leadSponsor":667,"locationsCount":46},"100631001","surgimedia-utilization-of-multimedia-for-enhanced-surgical-consent-100631001","NCT07494994","SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent","SURGIMEDIA","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n* Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of informed consent for study participation.\n* Scheduled to undergo a standard of care pancreaticoduodenectomy procedure.\n* English as the patient's self-reported preferred language.\n\nExclusion Criteria:\n\n* Inability to speak English.\n* Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.\n* Currently pregnant. If a participant becomes pregnant during the study, they will be withdrawn and replaced with a new participant if resources allow.",{"count":55,"type":21},[89],"Informed consent is an ethical and legal component of the pre-procedural process. Informed consent involves the explanation of procedural steps and discussion regarding the risks, benefits, and alternatives of the proposed procedure. The current informed consent process lacks standardization, and patient experience can vary widely depending on the provider obtaining consent. This pilot study aims to ensure high quality informed consent for patients undergoing a complex oncologic operation known as a pancreaticoduodenectomy (Whipple operation), through the creation of an educational video as a method of obtaining informed consent. This study will explore whether the application of an educational video as part of the informed consent process increases patient understanding, comfort, and overall satisfaction throughout the Whipple operative course. The primary objective of this study is to determine whether implementation of a multimedia video as an enhancement to surgical informed consent improves patient satisfaction, promotes understanding, and informs operative expectations. The desired outcome is to standardize the informed consent process to eliminate variability in the quality of the consent process and to mitigate the impact of healthcare barriers such as health literacy and language proficiency in the informed consent process.",[617],[658,659,660,661,662],"informed consent","pancreaticoduodenectomy","Whipple operation","educational video","complex surgical operation",{"date":599,"type":38},{"date":162,"type":21},{"date":666,"type":21},"2030-01",{"name":44,"class":45},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":672,"acronym":673,"eligibilityCriteria":674,"healthyVolunteers":368,"sex":17,"minAge":120,"maxAge":675,"enrollmentInfo":676,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":678,"conditions":679,"keywords":683,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":687,"leadSponsor":688,"locationsCount":689},"100632938","c-3002-enhancing-cervical-cancer-screening-access-and-follow-up-care-at-cascade-clinical-sites-in-the-united-states-100632938","NCT07520188","C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States","CASCADE3002","Aim 1b Inclusion Criteria\n\n* women with Human Immunodeficiency Virus (HIV) receive care\n* ages between 25- 49\n* eligible for cervical cancer screening per national US guidelines\n\nAim 1b Exclusion Criteria • Women without an intact cervix.\n\nAim 2 Inclusion Criteria:\n\n* Clinical team members who work and provide care to women living with HIV at three clinical locations: the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD; Ponce de Leon Clinic at Emory University in Atlanta, GA; and Albany Area Primary Health Care in Albany, GA. a\n* Clinical team members will include: providers (Physicians, Nurse practitioners, Physician's Assistants, Nurses, Nursing Assistants, Medical Assistants, Pharmacists), laboratory members, or other staff involved in clinic operations.\n\nAim 2 Exclusion Criteria\n\n• Individuals who do not work for the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD or the Ponce de Leon Clinic at Emory University in Atlanta, GA","49 Years",{"count":677,"type":21},3500,"The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer.\n\nCervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.",[680,681,126,682],"Human Immunodeficiency Virus (HIV)","Human Papillomavirus (HPV)","Cervical Precancer",[684],"screening",{"date":619,"type":38},{"date":76,"type":21},{"date":573,"type":21},{"name":44,"class":45},2,{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":695,"acronym":4,"eligibilityCriteria":696,"healthyVolunteers":368,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":22,"phases":698,"briefSummary":699,"conditions":700,"keywords":703,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":709,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":46},"100610248","phase-2-translation-of-acoustic-angiography-contrast-enhanced-super-resolution-cesr-imaging-100610248","NCT07225114","Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging","Academic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Patient had a diagnostic ultrasound study performed at University of North Carolina\n* Scheduled for a biopsy\n* Lesion visualized on ultrasound\n* Able to provide informed consent\n* Negative urine pregnancy test in women of child-bearing potential\n\nExclusion Criteria:\n\n* Institutionalized subject (prisoner or nursing home patient)\n* Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)\n* Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®)\n* Active cardiac disease including any of the following\n* Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association)\n* Unstable angina.\n* Severe arrhythmia (i.e., ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes).\n* Myocardial infarction within 14 days prior to the date of proposed Definity® administration.\n* Pulmonary hypertension\n* Cardiac shunts",{"count":87,"type":21},[57],"This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on prior ultrasound or cross-sectional imaging-will be imaged. Recruitment will be conducted such that ten patients are included from each anatomic region.\n\nThe fourth arm will consist of 10 healthy volunteers who will be imaged to allow optimization of imaging parameters. Optimization is is required again due to the use of a different ultrasound system employing a new imaging technique. Parameters such as frame rate, power, depth of imaging, and linear translation rate will be adjusted during this process.\n\nThe primary objectives of the study are to assess the sensitivity and specificity of Contrast Enhanced Super-Resolution (CESR) imaging in evaluating known lesions in the breast, liver, and kidney. These results will be compared with pathological findings. The secondary objectives are to compare the sensitivity and specificity of CESR imaging with those of traditional B-mode ultrasound in differentiating malignant from benign lesions in these same organs.",[27,701,702],"Kidney Neoplasms","Liver Neoplasms",[704,705,706,707,708],"Definity®","perflutren lipid","healthy volunteers","ultrasound","cross-sectional imaging",{"date":599,"type":38},{"date":711,"type":38},"2025-11-04",{"date":713,"type":21},"2028-12",{"name":44,"class":45},{"id":716,"slug":717,"hasResults":12,"nctId":718,"briefTitle":719,"officialTitle":720,"acronym":4,"eligibilityCriteria":721,"healthyVolunteers":12,"sex":119,"minAge":18,"maxAge":4,"enrollmentInfo":722,"targetDuration":4,"studyType":22,"phases":723,"briefSummary":724,"conditions":725,"keywords":729,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":734,"lastUpdatePostDateStruct":735,"startDateStruct":736,"completionDateStruct":737,"leadSponsor":738,"locationsCount":46},"100599003","phase-2-tirzepatide-in-women-with-obesity-and-endometrial-intra-epithelial-neoplasia-or-grade-1-endometrial-cancer-100599003","NCT07078838","Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer","A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* The subject is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age \\> 18 years at the time of consent.\n* ECOG ≤ 2 or Karnofsky Performance Status of \\>50\n* Histological or cytological evidence\u002Fconfirmation of endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid histology endometrial cancer (EC) and scheduled to undergo standard of care hysterectomy and staging.\n* Subject must have archival EC tissue available.\n* Body mass index of \\>30kg\u002Fm2\n* Demonstrate adequate organ function as defined in the protocol, all screening labs to be obtained within 28 days prior to initiating study treatment\n\nExclusion Criteria:\n\n* Active infection requires systemic therapy.\n* Subject is pregnant or breast breastfeeding, or planning to become pregnant at any time during the study\n* Taking any prescription medications or other drugs that influence weight change in the past 3 months.\n* Known sensitivities (i.e., urticaria and eczema) to GIP and GLP-1 receptor agonists.\n* Have type 1 diabetes mellitus or latent autoimmune diabetes in adults, or are receiving treatment with insulin.\n* Have a history of severe hypoglycemia or not be able to communicate an understanding of hypoglycemic symptoms.\n* Have a history of acute or chronic pancreatitis or serum lipase\u002Famylase \\>2X ULN or fasting triglyceride \\>500 mg\u002FdL at screening.\n* Have a diagnosis of gastroparesis, history of bariatric surgery, or a clinically significant gastric emptying abnormality.\n* Have a history or family history of multiple endocrine neoplasia, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.\n* Currently receiving another treatment for EIN or EC.\n* Any condition, in the opinion of the investigator, which would prohibit safe participation.",{"count":87,"type":21},[57],"The goal of this study is to determine the anti-proliferative effect of tirzepatide on the endometrium of patients with endometrial intra-epithelial neoplasia (EIN) and Grade 1 endometrial cancer (EC), by comparing archival endometrial biopsy samples of patients randomized to tirzepatide versus SOC (no tirzepatide) to their post-intervention hysterectomy specimens.\n\nIt was hypothesized that tirzepatide may help fight tumors in two ways: indirectly, by improving the body's overall metabolic health, and directly, by acting on abnormal cells in the uterus, such as those found in endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC). EIN is considered a precursor to EC. Tirzepatide may influence the tumor environment through key biological pathways related to insulin, fat metabolism, and mTOR signaling, all of which are often disrupted in individuals with obesity. Because both EIN and EC are strongly linked to obesity, tirzepatide could offer a promising dual benefit, promoting weight loss while also slowing or stopping tumor growth. The primary goal of this study is to determine whether tirzepatide can reduce cell proliferation in the lesions or tumors of patients with EIN and early- stage (Grade 1) EC.\n\nPatients will either be randomized to receive tirzepatide or no tirzepatide for 4 weeks prior to their hysterectomy surgery. Patients randomized to the tirzepatide arm will be given a glucose monitoring system for continuous monitoring with real-time alarms to alert of hypoglycemia. Patients will complete diaries during treatment to document compliance with medication and record any side effects.\n\nPatients will undergo standard of care surgery 7-10 days after the final dose of tirzepatide in order to minimize the risk of gastroparesis. During surgery (hysterectomy), an endometrial biopsy for uterine biopsy tissue will be collected.\n\nAt the 1-month post-operation visit, patients from both arms will be referred to an institutional weight loss clinic.",[726,727,728],"Endometrial Cancer","Endometrial Intraepithelial Neoplasia","Grade 1 Endometrial Endometrioid Carcinoma",[730,731,732,733],"tirzepatide","obesity","tumor environment","cell proliferation","2026-06-02",{"date":640,"type":38},{"date":138,"type":21},{"date":434,"type":21},{"name":44,"class":45},{"id":740,"slug":741,"hasResults":12,"nctId":742,"briefTitle":743,"officialTitle":744,"acronym":745,"eligibilityCriteria":746,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":747,"targetDuration":4,"studyType":22,"phases":749,"briefSummary":750,"conditions":751,"keywords":758,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":761,"lastUpdatePostDateStruct":762,"startDateStruct":763,"completionDateStruct":764,"leadSponsor":766,"locationsCount":46},"100639751","phase-2-effects-of-infusion-timing-on-treatment-response-in-solid-tumors-100639751","NCT07630168","Effects of Infusion Timing on Treatment Response in Solid Tumors","Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors","TIMED","Inclusion Criteria:\n\nCohort 1A and 1B:\n\n* Participants with metastatic non-small cell lung cancer (NSCLC).\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of consent.\n\nCohort 2A and 2B:\n\n* Participants with resectable head and neck squamous cell carcinoma (HNSCC)\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement\n* of the investigator.\n* Age ≥ 18 years at the time of consent.\n\nExclusion Criteria: For All Cohorts (1A,1B, 2A, 2B)\n\n* Subject is currently using steroids (prednisone ≥10 mg or its equivalent) and that cannot be discontinued at least 7 days before starting standard of care treatment.\n* Prior ICI (PD-1\u002FPD-L1\u002FCTLA4) treatment received less than 6 months from the time of screening.\n* Subject is participating in another treatment clinical trial.",{"count":748,"type":21},238,[57],"This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have either advanced or metastatic non-small cell lung cancer (NSCLC) or locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).The study tests the hypothesis that outcomes differ based on infusion timing (morning versus afternoon). Patients are divided into two cohorts by disease type: Cohort 1 includes NSCLC and Cohort 2 includes HNSCC. Within each cohort, patients are randomly assigned to receive infusions in the morning or afternoon, using a 2:1 ratio for NSCLC and a 1:1 ratio for HNSCC. All treatment and disease assessments follow standard medical care, and outcomes such as survival and treatment response are collected from medical records. Patients will be followed for up to 2 years.",[60,752,753,754,755,756,757],"Non-small Cell Lung Cancer","Metastatic Lung Cancer","Head and Neck Cancer","Metastatic Squamous Cell Carcinoma","Metastatic Head and Neck Cancer","Resectable Head and Neck Squamous-cell Carcinoma",[759,760],"programmed cell death protein 1","programmed death-ligand 1","2026-06-01",{"date":619,"type":38},{"date":761,"type":21},{"date":765,"type":21},"2033-01-01",{"name":44,"class":45},{"id":768,"slug":769,"hasResults":12,"nctId":770,"briefTitle":771,"officialTitle":772,"acronym":773,"eligibilityCriteria":774,"healthyVolunteers":12,"sex":119,"minAge":120,"maxAge":4,"enrollmentInfo":775,"targetDuration":4,"studyType":22,"phases":777,"briefSummary":778,"conditions":779,"keywords":787,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":761,"lastUpdatePostDateStruct":792,"startDateStruct":793,"completionDateStruct":794,"leadSponsor":796,"locationsCount":689},"100634904","phase-2-adjuvant-5-fluorouracil-following-thermal-ablation-to-improve-hpv-treatment-outcomes-in-women-with-hiv-in-kenya-100634904","NCT07545746","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya : The ASCEND Trial","ASCEND","Inclusion Criteria\n\n* Women aged 25 years or older\n* Known HIV-positive status\n* On antiretroviral therapy (ART) for at least 60 days prior to enrollment\n* Positive HPV screening test screening result\n* Able to provide informed consent in English, Swahili, or Dholuo\n* Agree to use dual contraception during dosing phase if of childbearing potential\n* Planning to remain in study locale for duration of study (48 weeks) Exclusion Criteria\n* Current pregnancy or breastfeeding\n* History of anogenital cancer (cervical, vulvar, or anal)\n* Current use of immunosuppressive medications\n* History of total hysterectomy\n* Known allergy to 5FU\n* Medical comorbidity that would interfere with study participation\n* Unwilling or unable to use contraception during study participation",{"count":776,"type":21},140,[57],"This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in Kenya. The trial will also assess the safety, adherence, and acceptability of 5FU. Starting four weeks after TA, participants will self-administer 5FU cream or matched placebo intravaginally once every other week for 12 applications, with clinic visits at weeks 2, 8, 16, 24, and 48 for evaluation. All participants will be followed up to 48 weeks.\n\nIt is hypothesized that, compared to placebo, 5FU will increase HPV clearance at 24 weeks and that the proposed dosing schedule will be safe, well-tolerated, and acceptable in this population. Together with data from other studies, this trial will provide evidence on the use of self-administered intravaginal 5FU to improve HPV treatment outcomes in WWH in low- and middle-income countries, where the burden of cervical cancer is highest.",[780,781,425,127,128,782,783,784,785,786],"HIV Infections","HPV Infection","CIN1","CIN","Cervical Intraepithelial Neoplasia Grade 3","Cervical Intraepithelial Neoplasia Grade 1","Cervical Intraepithelial Neoplasia Grade 2\u002F3",[788,789,790,791],"5-fluorouracil (5FU)","thermal ablation (TA)","placebo","intravaginal topical",{"date":734,"type":38},{"date":162,"type":21},{"date":795,"type":21},"2028-03",{"name":44,"class":45},""]